首页>
外国专利>
Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
展开▼
机译:针对T淋巴细胞和/或嗜酸性粒细胞的哮喘/过敏疗法
展开▼
页面导航
摘要
著录项
相似文献
摘要
A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure Nigella Sativa seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation. A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.
展开▼